Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies.

The Journal of biological chemistry - 16 Dec 2005

Glaser Scott M, Hughes Ina E, Hopp Jennifer R, Hathaway Karen, Perret Daniel, Reff Mitchell E

Abstract excerpt

HuCC49 deltaCH2 is a heavy chain constant domain 2 domain-deleted antibody under development as a radioimmunotherapeutic for treating carcinomas overexpressing the TAG-72 tumor antigen. Mammalian cell culture biosynthesis of HuCC49 deltaCH2 produces two isoforms (form A and form B) in an approximate 1:1 ratio, and consequently separation and purification of the desired form A isoform adversely impact process and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neoplasm
Share to Binding, Competitive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disulfides

Share to Hypoxia

Share to Mucins

Share to Oligonucleotides

Share to Peptide Mapping

Share to Spectrometry, Fluorescence

Source

Identifiers

PMID: 16221669
DOI: 10.1074/jbc.M508739200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies.PMID 16221669Read ↗

Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.Semantic proximity Read ↗

Expression, purification, and characterization of engineered antibody CH2 and VH domains.Semantic proximity Read ↗

Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imagingSemantic proximity Read ↗

Characterization of a new anti-LAG3 monoclonal for immuno-oncologySemantic proximity Read ↗

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.Semantic proximity Read ↗

High-Throughput Generation of Bipod (Fab × scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture.Semantic proximity Read ↗

Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design.Semantic proximity Read ↗

Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3Semantic proximity Read ↗

Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.Semantic proximity Read ↗

Combinatorial genome and protein engineering yields monoclonal antibodies with hypergalactosylation from CHO cellsSemantic proximity Read ↗

Modulation of the effector functions of a human IgG1 through engineering of its hinge region.Semantic proximity Read ↗

Impact of Light Chain Variants on the Expression of Therapeutic Monoclonal Antibodies in HEK293 and CHO CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.